ArticleCancer cell international2025
RPL22L1-Myc positive feedback loop drives lung adenocarcinoma progression.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRibosomal protein L22 like 1 (RPL22L1) plays an important role in some tumours. However, its role in lung adenocarcinoma (LUAD) is less studied. This study aimed to analyse the molecular mechanism of RPL22L1 in LUAD and to identify new targets for LUAD treatment.
methodsReal-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blot (WB) were employed to detect the mRNA and protein expression, respectively. The CCK8 assay, colony formation assay, and transwell migration and invasion assay were utilized to assess the effects of RPL22L1 on LUAD cell proliferation, migration, and invasion. A nude mouse subcutaneous graft tumor model was used to evaluate the effect of RPL22L1 on the proliferative capacity of LUAD cells in vivo. Dual fluorescent reporter gene assays, ubiquitination immunoprecipitation assays, and protein degradation assays were conducted to explore the potential mechanism of RPL22L1 in LUAD.
resultsThe study demonstrated that RPL22L1 could promote the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of LUAD cells. Mechanistically, the upregulation of RPL22L1 in LUAD activated the MAPK/ERK/Myc signaling pathway, which subsequently promoted the proliferation, migration, invasion, and EMT of LUAD cells. Furthermore, RPL22L1 was found to influence the ubiquitination of Myc protein, inhibit its degradation, and maintain its stability. Additionally, Myc protein could directly bind to the promoter region (-653 to -664) of RPL22L1 and enhance its transcriptional expression, forming a positive feedback loop to promote the developmental process of LUAD.
conclusionsOur study revealed a positive feedback loop between RPL22L1 and Myc that drove LUAD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.